OcellO

OcellO's mission is to help customer to discover the full potential of their compounds. OcellO offers in vitro assays which recapitulate and quantify complex human biology in a robust and high-throughput format. We test compounds for oncology, immuno-oncology, inflammation and cystopathy indications. We excel in in vitro 3D cell culture models and innovative high throughput imaging technologies. Our models are selected for clinically relevant, ‘near-vivo’ properties and consist of patient-derived cells and patient-derived xenografts (PDX models) grown in 3D as organoids, tumoroids or microtissues. We offer a broad collection of human tissue models, including most solid tumor types, immune-oncology, cystopathies (incl. polycystic kidney disease and cystic fibrosis) and Inflammatory Bowel Disease. Functional read-outs are established by image analysis using OcellO’s unique high throughput, high content screening platform. Features include cell proliferation, apoptosis, tumoroid size, organoid swelling, T cell infiltration, network formation, lumen formation and others. The high throughput format of our platform has proven ideal for in-depth functional profiling of a single compound or for screening of compound libraries in a single 3D disease model. OcellO would like to meet with companies (typically drug developers) that are interested in 1. validation in 3D cell/organoid models of their drug candidate(s) 2. screening services to discover new drug candidates in 3D cell models Please visit our site at OcellO.nl for more information and contact.

Pharmaceuticals
Leiden, Zuid-Holland
Founded in unknown
11-50 employees

OcellO's mission is to help customer to discover the full potential of their compounds. OcellO offers in vitro assays which recapitulate and quantify complex human biology in a robust and high-throughput format. We test compounds for oncology, immuno-oncology, inflammation and cystopathy indications. We excel in in vitro 3D cell culture models and innovative high throughput imaging technologies. Our models are selected for clinically relevant, ‘near-vivo’ properties and consist of patient-derived cells and patient-derived xenografts (PDX models) grown in 3D as organoids, tumoroids or microtissues. We offer a broad collection of human tissue models, including most solid tumor types, immune-oncology, cystopathies (incl. polycystic kidney disease and cystic fibrosis) and Inflammatory Bowel Disease. Functional read-outs are established by image analysis using OcellO’s unique high throughput, high content screening platform. Features include cell proliferation, apoptosis, tumoroid size, organoid swelling, T cell infiltration, network formation, lumen formation and others. The high throughput format of our platform has proven ideal for in-depth functional profiling of a single compound or for screening of compound libraries in a single 3D disease model. OcellO would like to meet with companies (typically drug developers) that are interested in 1. validation in 3D cell/organoid models of their drug candidate(s) 2. screening services to discover new drug candidates in 3D cell models Please visit our site at OcellO.nl for more information and contact.

Company Information

Industry
Pharmaceuticals
Company Type
Privately Held
Founded
unknown
Employee Range
11-50
Revenue Range
Not available

Location

Address
Leiden BioPartner Center Zuid-Holland Leiden
City
Leiden
Region
Zuid-Holland
Postal Code
2333 CH
Country
Netherlands

Web Presence

Websiteocello.nl
LinkedIn0 followers

Ready to automate your outreach?

Get unlimited access to our company database — complete with detailed profiles, funding info, and tech stacks — and start sending personalized emails with AI-powered follow-ups.

Frequently Asked Questions